Blackstone Life Sciences’ $250 Million Investment in Cellex Group

Noerr and Morgan, Lewis & Bockius advised Cellex Cell Professionals GmbH on the deal. Ropes & Gray advised Blackstone Life Sciences.

The Dresden-based Cellex Group announced the launching of a new company in the USA with Intellia Therapeutics, Inc.

The goal is to develop safer and more effective gene therapies for patients with hard-to-treat cancers and autoimmune diseases. The sole founding investor, Blackstone Life Sciences, has provided $250 million. The new jointly owned company, to be located in Cambridge, Massachusetts, will receive from Cellex its subsidiary GEMoaB and from Intellia its CRISPR/Cas9 genome editing technology.

Cellex Cell Professionals is offering a broad spectrum of services for clinical and research institutions in the field of cellular therapies.

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors.

The Noerr team included Jens Gehlich (Picture – Corporate/M&A), Sebastian Voigt (Private Equity), Prof. Sebastian Wündisch (IP, all Dresden, joint lead), Dr Fabian Badtke (Antitrust, Frankfurt), Dr Jennifer Bryant (Arbitration, Düsseldorf), Yvonne Dietzel (Employment, Dresden), Dr Anke Meier (Arbitration, Frankfurt), Dr Bärbel Sachs (Foreign Trade, Berlin), Angelika Schmid (Employment, Munich), Evelyn Schulz (Healthcare, Dresden), Anja Böhme (Tax), Doreen Annette Geidel (IP, both Dresden), Dr Isabel Jakobs (Compliance/Product Safety, Munich), Dr Vitaliy Kaminskiy (Tax, Berlin), Hans Kenschke (Corporate/M&A), Peter Scheuch (Tax), Susann Jahn (Healthcare), Dominik Pokora, Felix Ferdinand Winkler (both Corporate/M&A, all Dresden).

The Morgan, Lewis & Bockius team included Julio E. Vega (lead), Benjamin J. Stein (both Corporate/M&A, PE), James P. Carrigan, Byunghwi Rho (both IP).

The Ropes & Gray team was led by life sciences partners Michael Beauvais and Abigail Gregor and life sciences associates Rajarshi Banerjee and Adam Stein (all of Boston) and included employment & benefits partners Megan Bisk and Renata Ferrari, tax partner Pam Glazier (all of Boston), litigation & enforcement partner Ama Adams (Washington, D.C.), life sciences regulatory & compliance partner Al Cacozza (Washington, D.C.), IP transactions counsel Emilia Cannella (Boston) and Ryan Murphey (New York), litigation & enforcement counsel Brendan Hanifin (Chicago), Deidre Johnson (Boston) and Lisa Kaltenbrunner (London).

Involved fees earner: James Carrigan – Morgan Lewis & Bockius; Byunghwi Rho – Morgan Lewis & Bockius; Benjamin Stein – Morgan Lewis & Bockius; Julio Vega – Morgan Lewis & Bockius; Doreen Annette Geidel – Noerr; Fabian Badtke – Noerr; Anja Böhme – Noerr; Jennifer Bryant – Noerr; Yvonne Dietzel – Noerr; Jens Gehlich – Noerr; Susann Jahn – Noerr; Isabel Jakobs – Noerr; Vitaliy Kaminskiy – Noerr; Hans Kenschke – Noerr; Anke Meier – Noerr; Dominik Pokora – Noerr; Bärbel Sachs – Noerr; Peter Scheuch – Noerr; Angelika Schmid – Noerr; Evelyn Schulz – Noerr; Sebastian Voigt – Noerr; Felix Ferdinand Winkler – Noerr; Sebastian Wündisch – Noerr; Ama Adams – Ropes & Gray; Rajarshi Banerjee – Ropes & Gray; Michael Beauvais – Ropes & Gray; Megan Bisk – Ropes & Gray; Albert Cacozza – Ropes & Gray; Emilia Cannella – Ropes & Gray; Renata Ferrari – Ropes & Gray; Pamela Glazier – Ropes & Gray; Abigail Gregor – Ropes & Gray; Brendan Hanifin – Ropes & Gray; Deidre Johnson – Ropes & Gray; Lisa Kaltenbrunner – Ropes & Gray; Ryan Murphey – Ropes & Gray; Adam Stein – Ropes & Gray;

Law Firms: Morgan Lewis & Bockius; Noerr; Ropes & Gray;

Clients: Blackstone Life Sciences; Cellex Cell Professionals GmbH;

Federica Tiefenthaler

Author: Federica Tiefenthaler